—

PACS Group, Inc. (PACS) — the peer cohort

As of 2026-10-15 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

PACS Group, Inc. ranks 5 of 8 in its cohort on the Closelooknet composite (55/100) — the cohort is led by Halozyme Therapeutics Inc at 75/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
PACS PACS Group, Inc. 55 81 39 53 ok 3.5%
FMS Fresenius Medical Care Corporation 51 43 34 84 info 16.2%
ENSG The Ensign Group Inc 48 43 34 43 info 18.2%
RHC.AU Ramsay Health Care Ltd 45 91 22 52 ok 2%
HALO Halozyme Therapeutics Inc 75 98 94 47 ok 0.7%
DXCM DexCom Inc 66 87 80 34 watch 9.8%
ONC BeiGene, Ltd. 64 84 63 30 ok 2.9%
MEDP Medpace Holdings Inc 64 87 74 28 ok 7.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-15

Quick answers

Who are PACS Group, Inc.'s peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Fresenius Medical Care Corporation (FMS), The Ensign Group Inc (ENSG), Ramsay Health Care Ltd (RHC.AU), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM), BeiGene, Ltd. (ONC), Medpace Holdings Inc (MEDP).

How does PACS score against its peers?

PACS Group, Inc.'s composite reads 55/100, ranking 5 of 8 in its cohort as of 2026-10-15; the cohort's highest composite is Halozyme Therapeutics Inc at 75/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Medical Care Facilities, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.